Key result
I-2PP2A/SET suppresses cell proliferation by inhibiting the G1/S transition and MEK/ERK signaling.
Why the study?
The regulatory role of I-2PP2A/SET on cell proliferation and the MEK/ERK pathway was not fully understood.
I-2PP2A/SET negatively regulates cell growth by inhibiting the G1/S transition and the MEK/ERK pathway, suggesting a potential tumor suppressor function.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for I-2PP2A/SET as tumor suppressor; human validation required before clinical consideration.
I-2PP2A/SET, the translocation breakpoint-encoded protein expressed in acute undifferentiated leukemia, was identified as an inhibitor of protein phosphatase 2A (PP2A). Induction of exogenous I-2PP2A/SET at a ratio of 1:1 to the endogenous protein resulted in suppression of cell proliferation. In contrast, siRNA-mediated depletion of I-2PP2A/SET resulted in enhanced cell proliferation. Depletion of I-2PP2A/SET was accompanied with a decrease in the number of cells in G1 and an increase in cells in S phase. To examine the mode of action by which I-2PP2A/SET suppresses cell proliferation, we determined the effect of over-expressed I-2PP2A/SET on ERK activation. I-2PP2A/SET suppressed activation of ERK following EGF stimulation but did not affect activation levels of stress kinases, JNK and p38. By contrast, knocking down I-2PP2A/SET by siRNA resulted in enhancement of ERK and MEK activations, suggesting that I-2PP2A/SET negatively regulates MEK/ERK. These data suggest that I-2PP2A/SET negatively regulates cell growth by inhibiting the G1/S transition and inhibiting the MEK/ERK pathway stimulated by external stimuli. These data demonstrate that I-2PP2A/SET potentially functions as a tumor suppressor.
No takes yet. Share an insight, caveat, or question.
Fukukawa et al. (2005) studied Acute undifferentiated leukemia. I-2PP2A/SET induction or depletion vs. Endogenous levels was evaluated on Cell proliferation and ERK activation. I-2PP2A/SET negatively regulates cell growth by inhibiting the G1/S transition and the MEK/ERK pathway, suggesting it potentially functions as a tumor suppressor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: